Objective To explore the characteristics of oncoprotein expression of c-fos and c-jun in hypertrophic scars and chronic dermal ulcers and their regulation of basic fibroblast growth factor (bFGF). Methods Tissues of...Objective To explore the characteristics of oncoprotein expression of c-fos and c-jun in hypertrophic scars and chronic dermal ulcers and their regulation of basic fibroblast growth factor (bFGF). Methods Tissues of hypertrophic scars (n=8), chronic dermal ulcers (n=8) and normal skin (n=5) were taken from 21 patients with burns and chronic dermal ulcers in operation. The ABC immunohistochemical method was used to characterize the gene product expression of c-fos, c-jun and bFGF in the above tissues. Results In normal skin, both c-fos and c-jun protein expression and bFGF protein expression were observed. The signals of both oncoproteins were localized mainly in subcutaneous fibroblasts, but, positive expression of the bFGF protein was mainly in keratinocytes. In hypertrophic scars, positive expression of both oncoproteins could be found mainly in fibroblasts, but bFGF was mainly in fibroblasts and endothelial cells. In chronic dermal ulcers, endothelial cells, some of inflammatory cells and fibroblasts were positive for both of oncoproteins, but the expression of bFGF was only seen in fibroblasts and endothelial cells. Conclusions The results indicate that the interaction between both oncoproteins and bFGF exists, and the regulating action between protooncogenes and bFGF is a major course in wound healing. The different expressions of c-fos and c-jun gene products play an important role in regulate bFGF action, thus affecting wound healing.展开更多
Objective To evaluate the effect of recombinant bovine basic fibroblast growth factor(rbFGF) on accelerating healing of burn wounds, donor sites and chronic dermal ulcers in multicenters Methods One thousand and t...Objective To evaluate the effect of recombinant bovine basic fibroblast growth factor(rbFGF) on accelerating healing of burn wounds, donor sites and chronic dermal ulcers in multicenters Methods One thousand and twenty four patients with burns, donor sites and chronic dermal ulcers were recruited for this prospective and multicenter clinical trial and another 641 patients with the similar wounds were used as controls All patients were divided into three groups: burn group, donor site group, and chronic dermal ulcer group In the burn group, 654 patients with superficial second degree burns( superficial Ⅱ ) or deep second degree burns( deep Ⅱ ) were treated topically with either recombinant bovine basic fibroblast growth factor (rbFGF plus vehicle, rbFGF 150 ?AU/cm 2/day, 330 patients) or placebo (vehicle without rbFGF, 324 patients) In the donor site group, 509 patients were treated with rbFGF and 317 patients with placebo in a similar way as described elsewhere In the chronic dermal ulcer group, 185 patients were treated with rbFGF and the controls were themselves Photography, histological evaluation and clinical examination were used to evaluate the results of wound healing Results All of superficial second degree burns, deep second degree burns and the donor sites treated with recombinant bovine basic fibroblast growth factor had an accelerated rate of granulation tissue formation and epidermal regeneration as compared with that in the controls Superficial second degree burns and deep second degree burns treated with recombinant bovine basic fibroblast growth factor healed in 9 89±2 45 and 17 04±4 56 days, respectively, whereas the average healing time in those receiving placebo was 12 35±2 74 and 21 21±4 88 days The donor sites treated with rbFGF or placebo healed in 10 68±4 55 and 14 74±6 46 days, respectively All chronic dermal ulcers except 12 patients treated with rbFGF healed within 6 weeks Histological evaluation of punch biopsy specimens from the burn wounds, donor sites and chronic dermal ulcers seven days after treatment supported the impression of accelerated wound healing after rbFGF treatment Conclusions rbFGF is effective in shortening the wound healing time and improving the wound healing quality Accelerating wound healing is of clinical benefit in reducing the length of hospitalization, costs and emotional burden of the patient展开更多
文摘Objective To explore the characteristics of oncoprotein expression of c-fos and c-jun in hypertrophic scars and chronic dermal ulcers and their regulation of basic fibroblast growth factor (bFGF). Methods Tissues of hypertrophic scars (n=8), chronic dermal ulcers (n=8) and normal skin (n=5) were taken from 21 patients with burns and chronic dermal ulcers in operation. The ABC immunohistochemical method was used to characterize the gene product expression of c-fos, c-jun and bFGF in the above tissues. Results In normal skin, both c-fos and c-jun protein expression and bFGF protein expression were observed. The signals of both oncoproteins were localized mainly in subcutaneous fibroblasts, but, positive expression of the bFGF protein was mainly in keratinocytes. In hypertrophic scars, positive expression of both oncoproteins could be found mainly in fibroblasts, but bFGF was mainly in fibroblasts and endothelial cells. In chronic dermal ulcers, endothelial cells, some of inflammatory cells and fibroblasts were positive for both of oncoproteins, but the expression of bFGF was only seen in fibroblasts and endothelial cells. Conclusions The results indicate that the interaction between both oncoproteins and bFGF exists, and the regulating action between protooncogenes and bFGF is a major course in wound healing. The different expressions of c-fos and c-jun gene products play an important role in regulate bFGF action, thus affecting wound healing.
文摘Objective To evaluate the effect of recombinant bovine basic fibroblast growth factor(rbFGF) on accelerating healing of burn wounds, donor sites and chronic dermal ulcers in multicenters Methods One thousand and twenty four patients with burns, donor sites and chronic dermal ulcers were recruited for this prospective and multicenter clinical trial and another 641 patients with the similar wounds were used as controls All patients were divided into three groups: burn group, donor site group, and chronic dermal ulcer group In the burn group, 654 patients with superficial second degree burns( superficial Ⅱ ) or deep second degree burns( deep Ⅱ ) were treated topically with either recombinant bovine basic fibroblast growth factor (rbFGF plus vehicle, rbFGF 150 ?AU/cm 2/day, 330 patients) or placebo (vehicle without rbFGF, 324 patients) In the donor site group, 509 patients were treated with rbFGF and 317 patients with placebo in a similar way as described elsewhere In the chronic dermal ulcer group, 185 patients were treated with rbFGF and the controls were themselves Photography, histological evaluation and clinical examination were used to evaluate the results of wound healing Results All of superficial second degree burns, deep second degree burns and the donor sites treated with recombinant bovine basic fibroblast growth factor had an accelerated rate of granulation tissue formation and epidermal regeneration as compared with that in the controls Superficial second degree burns and deep second degree burns treated with recombinant bovine basic fibroblast growth factor healed in 9 89±2 45 and 17 04±4 56 days, respectively, whereas the average healing time in those receiving placebo was 12 35±2 74 and 21 21±4 88 days The donor sites treated with rbFGF or placebo healed in 10 68±4 55 and 14 74±6 46 days, respectively All chronic dermal ulcers except 12 patients treated with rbFGF healed within 6 weeks Histological evaluation of punch biopsy specimens from the burn wounds, donor sites and chronic dermal ulcers seven days after treatment supported the impression of accelerated wound healing after rbFGF treatment Conclusions rbFGF is effective in shortening the wound healing time and improving the wound healing quality Accelerating wound healing is of clinical benefit in reducing the length of hospitalization, costs and emotional burden of the patient
